Evoke Pharma’s $14.4 Million Shares Offering

Sheppard Mullin advised the underwriter on the deal.

Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, announced the completion of its follow-on offering of 5,750,000 shares of its common stock, including 750,000 shares of common stock sold pursuant to the underwriter’s full exercise of its option to purchase additional shares, at a price to the public of $2.50 per share. The gross proceeds from the offering were approximately $14.4 million, before underwriting discounts and commissions and estimated offering costs.

Evoke intends to use the net proceeds from the offering for working capital and general corporate purposes, including funding commercialization activities, research and development activities, clinical trial expenditures, and possible acquisition of new technologies or products.

Laidlaw & Company (UK) Ltd. acted as sole book-running manager for the offering.

Evoke is a specialty pharmaceutical company focused primarily on the commercialization and development of drugs to treat GI disorders and diseases. The Company developed GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

The Sheppard Mullin corporate team included partner Richard Friedman (Picture) and associates Nazia Khan and Brett Uslaner. Special assistance was provided by partners Allison Fulton and Jing Liu and associate Paul Chang.

Involved fees earner: Richard Friedman – Sheppard Mullin; Allison Fulton – Sheppard Mullin; Nazia Khan – Sheppard Mullin; Jing Liu – Sheppard Mullin;

Law Firms: Sheppard Mullin;

Clients: Laidlaw & Company;


Author: Ambrogio Visconti